This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Age-related Macular Degeneration, Coronary Artery Disease or Cerebrovascular Disorders
and you are
between 50 and 90
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events. The main objective of study is to reveal contraindications for ranibizumab prescription in patients with history of coronary artery disease and cerebrovascular events. Moreover, an association between management with ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest as well.

Provided treatments

  • Drug: 0.5 mg of ranibizumab
  • Procedure: 0.5 mg of ranibizumab + photodynamic therapy
  • Other: Sham injection

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01319188. The sponsor of the trial is Ural Medical University and it is looking for 380 volunteers for the current phase.
Official trial title:
Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)